- Company
- Samsung Bioepis partners with Teva for Soliris biosimilar
- by Cha, Jihyun Jan 14, 2025 05:56am
- Samsung Bioepis announced on the 12th that it has signed a commercialization partnership agreement with the multinational pharmaceutical company Teva Pharmaceutical Industries to launch Epysqli, a biosimilar of the rare disease treatment Soliris (eculizumab), in the U.S. market. Epysqli is the first hematology biosimilar developed by Sam
- Company
- Will biotech companies continue 'K-Bio' success?
- by Moon, sung-ho Jan 13, 2025 05:53am
- Korean pharmaceutical and biotech companies have successfully outlicensed new drugs in various fields, including cancer, autoimmune disease, and Alzheimer's disease. However, compared to the year before, analysis suggests that the number of out-licensed cases decreased. Despite such a slowdown, companies focusing on global new drug developmen
- Company
- Samsung Bioepis to indirectly sell Soliris biosimilar in US
- by Cha, Jihyun Jan 13, 2025 05:53am
- Samsung Bioepis has signed a partnership agreement with the multinational pharmaceutical company Teva Pharmaceuticals to commercialize biosimilars of rare disease treatments in the United States. Samsung Bioepis will launch the biosimilar through Teva in the U.S. market in the first half of this year. Unlike in Europe, where Samsung Bioepis h
- Company
- Wegovy can be prescribed in tertiary hospitals in KOR
- by Eo, Yun-Ho Jan 13, 2025 05:53am
- The obesity drug ‘Wegovy’ can now be prescribed in tertiary hospitals in Korea. According to industry sources, Novo Nordisk Korea's Wegovy (semaglutide) has passed the drug committees (DCs) of Korrea’s “Big 5 medical institutions,” including Samsung Medical Center, Seoul National University Hospital, and Sinchon Severance Hospital.
- Company
- Imported API from China·India reaches 50%
- by Kim, Jin-Gu Jan 13, 2025 05:53am
- It has been reported that half of the active ingredients (API) imported to South Korea are produced in China and India. The percentage of imported active ingredients originating from China·India surpassed 50% in two consecutive years. The percentage of imported API from India has robustly increased recently. Indian API imports were below 10
- Company
- Sanofi’s Hexaxim is included in NIP from this year
- by Whang, byung-woo Jan 10, 2025 05:52am
- Sanofi announced on the 9th that Hexaxim, its hexavalent combination vaccine for infants, has been included in Korea’s National Immunization Program (NIP). With its introduction to the NIP, Hexaxim can now be administered free of charge at designated medical institutions under the National Immunization Program for Children. As the fir
- Company
- Hexaxim may be administered in general hospitals in Korea
- by Eo, Yun-Ho Jan 10, 2025 05:52am
- Hexaxim, a hexavalent combination vaccine for infants that was included in the National Immunization Program, may now be administered in general hospitals. According to industry sources, Sanofi Korea's Hexaxim prefilled syringe has now passed the drug committees (DCs) of 17 medical institutions nationwide, including Seoul National Univers
- Company
- Lilly Korea releases Ebglyss for atopic dermatitis in Korea
- by Whang, byung-woo Jan 10, 2025 05:52am
- Lilly Korea announced on the 9th that it had launched Ebglyss (lebrikizumab) in Korea for the treatment of moderate-to-severe atopic dermatitis.&160; Ebglyss is a novel biologic agent that selectively blocks cytokine interleukin (IL)-13, a major cause of atopic dermatitis. It was approved by the Ministry of Food and Drug Safety in Au
- Company
- Leclaza’s new trial data shows improved OS
- by Son, Hyung Min Jan 9, 2025 05:57am
- The Leclaza plus Rybrevant combination achieved statistically significant overall survival (OS) results. Johnson & Johnson expects Leclaza plus Rybrevant to extend OS by more than a year compared to Tagrisso monotherapy. The positive OS outcome for the combination strengthens its potential to become the first-line standard of care for EGFR-p
- Company
- Vabysmo approved for retinal vein occlusion macular edema
- by Whang, byung-woo Jan 9, 2025 05:56am
- Roche Korea announced on the 8th that Vabysmo has been approved by the Ministry of Food and Drug Safety (MFDS) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. With the approval, Vabysmo is now approved for 3 indications in Korea, including as a treatment for ▲neovascular (wet) age-relate
